Covid-19 testing brief - May 18, 2020 - Avalon Healthcare Solutions
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
May 18, 2020
Covid-19
testing brief
from Avalon Healthcare Solutions
contents
Avalon is the expert in
laboratory and medical
specialty drug benefit
Avalon Laboratory Network
management. Our solutions
Capability & Capacity Report
are driven by evidence-based
FDA Issues First COVID-19 EUA medical science. Avalon’s
for Antigen Testing core program includes full
delegation of Routine Testing
IDSA Releases New Guidelines Management, Genetic Testing
on COVID-19 Testing Management, Independent
Laboratory Network
Making Sense of Coding Possibilities
to Track COVID-19 Claims for Cost Management, and Medical
Sharing Requirements and FWA Specialty Rx Management.
Our comprehensive solutions
References manage all out-patient
lab spend across all lab
testing types. Avalon helps
physicians, consumers, and
for more information, please contact us:
payers maximize the cost-
Barry S. Davis, Chief Growth Officer Fred Barry, VP, Business Development effective use of diagnostic
201-218-3425 | barry.davis@avalonhcs.com 714-615-1889 | Fred.Barry@avalonhcs.com laboratory tests. Avalon
Sara Sabin, VP, Business Development Joy Harris, Dir. Business Development Healthcare Solutions is a
845-591-4725 | sara.sabin@avalonhcs.com 813-751-3814 | joydana.harris@avalonhcs.com registered d/b/a of Avalon
Angelo Devita, VP, Business Development Health Services, LLC.
215-872-2202 | Angelo.Devita@avalonhcs.com
Avalon Laboratory Network
Capability & Capacity Report
The current daily capacity for RT-PCR testing exceeds 230,000 tests/day. The following labs have reported their
intent to increase capacity:
LabCorp to increase by June: Quest Diagnostics to increase by BioReference Laboratories to
• RT-PCR capacity increase mid-May: increase by June:
to 150,000 tests/day • Antibody capacity increase • Antibody capacity increase
• Antibody capacity increase to 200,000 tests/day to 400,000 tests/day
to 300,000 tests/day
RT-PCR MULTI CAPA- TURN- ANTIBODY CAPA- TURN-
LAB HEALTHPLAN Y/N PLAT- CITY AROUND TESTING METHODOLOGY CITY AROUND
FORMS? (PER TIME Y/N (PER DAY) TIME
DAY)
LabCorp SC, NC Y Y 75,000 1-3 days Y Elisa & 70,000 1-3 days
Chemiluminscence
Quest SC, NC, CBC, VT Y Y 50,000 1-2 days Y Elisa & 150,000 1-2 days
Chemiluminscence
BioReference SC, NC, CBC, VT Y Y 35,000 1-2 days Y Chemiluminscence 100,000 3 days
Sonic CPL (Clinical SC Y Y 20,000 1-3 days Y Elisa 100,000 24 hrs
Pathology Lab)
Mako Medical Lab SC, NC Y Y 12,000 1-2 days Y Elisa & 11,000 1 day
Chemiluminscence
Premier Medical Lab SC Y Y 10,000 1-3 days Y Elisa 6,000 1-2 days
Eurofins-Diatherix** SC, NC, CBC, VT Y N 5,000 1-2 days Y Chemiluminscence 5,000 2-4 days
MDL (Medical SC, NC, CBC, VT Y N 5,000 1-2 days Y Elisa 1,000 3 days
Diagnostic Lab)
Neogenomics SC, NC, CBC, VT Y Y 3,400 1-4 days N N/A
AIT (American Institute SC, NC, CBC Y Y 2,600 1-2 days N N/A
of Tox)
BAKO SC, NC, CBC, VT Y N 2,500 1-2 days N N/A
Precision Genetics SC, NC Y N 2,400 1 day N N/A
PathGroup NC Y Y 2,200 1-2 days Y Elisa & 500 1 day
Chemiluminscence
LabTech SC, NC Y Y 2,000 1-2 days Y Chemiluminscence 3,000 1 day
Luxor SC Y Y 1,000 1-3 days Y Elisa 350 1-2 days
Wake Medical Lab NC Y Y 1,000 1 day N N/A
Consultants
SMA CBC Y Y 1,000 1-2 days N N/A
Inform Diagnostics SC, NC, CBC, VT Y N 200 1-2 days N N/A
Data from the COVID Tracking
Project indicates a current 3-day
average (May 11-13) of 338,053 tests
performed per day. The Harvard
Global Health Initiative suggests
that 500,000 to 700,000 tests are
needed each day to support the
re-opening of the US economy.
WHAT ARE THE LIMITATIONS
TO TESTING?
A recent survey of laboratories
denotes the following hurdles to
testing for COVID-19:
2020 lab claims originating from each place of service show a significant
reduction in April, with physician office labs beginning a steeper drop in
• 58% noted a shortage of NP
March. Each line represents claim volume vs. January 2020, for example,
swabs (used in RT-PCR testing)
hospital claim volume in April was slightly over 50% of the claim volume
• 57% noted a shortage of PPE in January. 2019 data for the same time period shows laboratory claim
required to protect sample volume consistent month-to-month with no reduction (data not shown).
collection personnel
• 47% noted difficulty obtaining
reagents or the tests necessary to specimen would be collected. are reserved for individuals with
perform testing However, the COVID crisis upset symptoms, persons that have been
this process in two ways. First, exposed to an infected individual
This information is interesting in the infectious nature of the virus or for frontline healthcare workers.
that it indicates that the collection dictated special precautions for In these cases, there is a medically
of subject specimens is the larger specimen collection. Second, necessary reason for testing.
hurdle to testing than is the actual physician offices and lab collection However, there are additional
performance of the test. Access is depots were no longer in service. screening opportunities that are
also a contributor to the lower daily The enclosed chart demonstrates more data driven:
capacity for testing. Prior to the the issue with respect to access to
COVID-19 epidemic in the US, the • Employer testing to assure
physician office testing.
physician office was the primary the welfare and safety of their
WHERE IS TESTING FOR employee base (parallel to
“gateway” for laboratory testing. COVID-19 TAKING PLACE?
An individual would visit their employee drug screening)
physician, undergo an exam and The news outlets frequently • Serological surveys.
if necessary, receive an order for a identify sites where testing is These are epidemiological or
lab test. The specimen for testing taking place, often in a “drive- prevalence studies in designated
would be collected in the office or in” format where the individual communities funded by federal,
the individual would be directed remains in their car and specimens state, and local public health
to a lab site where the appropriate are collected. Typically, these sites entities.
FDA ISSUES FIRST COVID-19
EUA FOR ANTIGEN TESTING
proteins (N) help package the viral
detects the N protein of either
genome. The Quidel Corporation the SARS-CoV or SARS-CoV-2
has been granted an EUA for their virus from an upper respiratory
Sofia®2 SARS Antigen FIA lateral sample (either a nasal swab or
flow immunofluorescent sandwich nasopharyngeal swab). First, the
assay for the qualitative detection
sample is placed in a reagent tube
of the nucleocapsid (N) protein so that any virus, if present, is
antigen of SARS-CoV-2 for use in broken apart to allow for the N
individuals suspected of COVID-19 proteins to be exposed. The sample
by their healthcare provider.3 This
then travels from the sample well,
test has been approved as a point-down a test strip—where the term
On May 8, 2020, the FDA issued the of-care (POC) test.5 “lateral flow” is derived—where the
first Emergency Use Authorization proprietary reagents will recognize
(EUA) for antigen testing for How does this test work? The test any N proteins and trap them in
COVID-19. An antigen is a protein,
or part of a protein, located on a
virus or bacteria that can cause an
immune response in an individual.
What makes this method of testing
distinct from antibody testing
is that antigen testing directly
measures the presence of the virus
in a person whereas antibody
testing is measuring the patient’s
response to an infection. Located
on the surface of the virus that
Figure 1: Illustration of COVID-19. Provided by the Public Health Image
causes COVID-19, the SARS-CoV-2
Library of the Centers for Disease Control and Prevention (CDC)2, this
virus, are proteins, such as the spike illustration shows the structures associated with coronaviruses. Proteins, such
proteins (S) (Figure 1), while other as the S protein (denoted in red), may be antigens that can possibly be used for
proteins called the nucleocapsid direct antigen testing.
place on the strip. The test requires (47/59 of positive samples tested swabs were spiked with a higher
at least 15 minutes to develop prior “positive”). They report 100% NPA or concentration of the virus. Then, all
to analysis. The strip can then be Negative Percent Agreement—all 84 30 swabs were tested and compared
read by the Sofia®2 system that negative samples tested “negative”. to 47 control (“unspiked”) samples.
measures the fluorescent signal The second study used a total of 48
In this study, none of the “unspiked”
from the proprietary reagents. samples. Again, 80% of the positive
control samples tested “positive”
The Sofia®2 system allows the user samples tested “positive”; however,
while all 30 of the “spiked” samples,
to have two different modes for only a total of five positive samples
regardless of the concentration,
analysis—“Walk Away” and “Read were included within this second
tested positive. Quidel also tested
Now”. study.
the limit of detection (LoD) of
the Sofia®2 SARS Antigen FIA
test. LoD is typically measured by
determining the TCID50 (median
tissue culture infective dose). The
TCID50 is the amount where 50%
of the cells within a sample are
infected.6
For the Sofia®2 SARS Antigen FIA
test, the LoD for a direct swab sample
has a TCID50 of 113 mL whereas
For the “Walk Away” mode, the user The remaining 43 samples were
it is 850 mL if the initial sample is
will insert the test cassette strip all negative samples. This study
from a swab sample that has been
into the system, and the results will reports a sensitivity of 80.0%, but
diluted into 3 mL of reagent. Finally,
be displayed in 15 minutes because a 95% confidence interval range of
Quidel also checked this antigen
the test will be developed while 37.6% - 96.4%. A third supportive
test for possible cross-reactivity
in the instrument. In “Read Now” study was also performed. In this
with a number of microorganisms
mode, the user must have already study, thirty swabs were taken.
and other viruses. It shows no
allowed at least 15 minutes for the Twenty of these swabs were spiked
cross-reactivity with any of the
test to develop prior to inserting with one lower concentration of
microorganisms or viruses tests
it into the instrument. Then, the the virus while the remaining ten
other than SARS-CoV.
Sofia®2 system will display the
result within one minute.
To address the clinical
performance, two primary studies
were performed. Both studies only
used frozen samples. The first
study used 143 samples with 80%
PPA or Positive Percent Agreement
Of note, it does not cross-react outbreak of 2003. It should be noted
with human coronavirus 229e, that there is no current outbreak of
OC43, NL63, or MERS-CoV (heat- SARS.
inactivated); however, they did not
• This test also does not distinguish
check for possible cross-reactivity
between “live” (viable) virus and
with the other known human
non-viable virus. Consequently,
coronavirus (HKU1) due to a lack
the test results do not necessarily
of availability at this time. This is
correlate with viral culture results
noteworthy since this coronavirus
performed on the same sample.
is associated with the common
cold. • This test is only for the qualitative
use on a sample from either a nasal
swab or a nasopharyngeal swab.
It has not been approved for use, • Positive test results do not rule
at this time, on any other sample, out co-infections, and negative
such as saliva. results do not “rule in” other non-
SARS viral or bacterial infections.
• Negative test results can occur
if the viral level is below the lower • The clinical performance assays
limit of the test. All negative results submitted for FDA approval were
“should be treated as presumptive performed using frozen samples;
and confirmed with an FDA the test may have a different
authorized molecular assay, if performance when used with a
necessary, for clinical management, fresh sample (such as in a point-of-
What are the limitations to the including infection control”3 care setting).
Sofia®2 SARS Antigen FIA test? [emphasis added]
• “If the differentiation of specific
Limitations include the following:
SARS viruses and strains is needed,
• This test must be performed additional testing, in consultation
using the Sofia®2 system, and the with state or local public health
test must be performed accurately departments is required.”3
following the test procedure.
• As previously noted, the
Failure to do so can adversely affect
company did not check this test
the performance of the test and
(as of publication date) for cross-
may invalidate the results.
reactivity with human coronavirus
• A positive test cannot distinguish HKU1 due to a lack of availability
between a SARS-CoV or a SARS- of that strain. This is notable since
CoV-2 infection. SARS-CoV is this particular virus is associated
the virus that caused the SARS with upper respiratory conditions
such as the common cold.
IDSA Releases New Guidelines
on COVID-19 Testing
recommendation is made for 3. They strongly recommend
situations where testing and/or RNA testing (versus no testing) in
personal protective equipment asymptomatic individuals before
(PPE) are limited. immunosuppressive procedures
regardless of a known exposure to
The Infectious Diseases Society of The panel made 15 recommendations COVID-19.
America (IDSA) on May 6, 2020, concerning the use of nucleic acid
released their guidelines on the testing as follows: 4. They suggest (conditional
diagnosis of COVID-19. At this recommendation) using a
1. They strongly recommend nasopharyngeal, mid-turbinate,
time, they focus solely on the use
using a nucleic acid amplification or nasal swab rather than
of targeted nucleic acid testing,
test (NAAT), such as RT-PCR, in oropharyngeal swab or saliva
such as RT-PCR, because “[a]
symptomatic patients even when sample for testing.
t the time of this review, there
clinical suspicion for COVID-19 is
was little evidence to inform use
low. 5. They suggest (conditional
of serologic testing.”4 The IDSA
recommendation) that either a
convened a multidisciplinary panel 2. They strongly recommend RNA patient or a healthcare provider
of experts to review the research testing in immunocompromised can collect a nasal or mid-turbinate
and literature on the available asymptomatic individuals who sample in a symptomatic patient.
diagnostic testing for COVID-19. are being admitted to the hospital
The panel used the Grading of regardless of exposure to COVID-19. 6. They make NO recommendation
Recommendations Assessment, for or against the use of rapid
Development and Evaluation nucleic acid testing (where the test
(GRADE) methodology to assess time is within one hour) versus
the evidence of the studies and to standard RNA testing. They cite a
make their recommendations. knowledge gap. More research is
needed.
A primary recommendation
implies that diagnostic testing and 7. They suggest (conditional
specimen collection devices are recommendation) RNA testing in
available whereas a contingency asymptomatic individuals who are
either known or suspected to have individual and not repeat testing if
been exposed to COVID-19. low clinical suspicion of COVID-19.
8. They suggest against (conditional 11. The suggest (conditional
recommendation) RNA testing in recommendation) repeat testing
asymptomatic individuals with no of an initial negative result in
known contact with COVID-19 who a symptomatic individual be
are being hospitalized in areas with performed only if there is an
low prevalence. They consider a low intermediate or high clinical
prevalence rate to be less than 2% of suspicion of COVID-19.
the community.
12. For hospitalized patients,
they suggest (conditional
recommendation) initially
collecting an upper respiratory who are undergoing major time-
tract sample. Then, collect the sensitive surgeries.
lower respiratory tract sample
if the initial upper respiratory
14. They suggest (conditional
tract sample result is negative but
recommendation) RNA testing in
suspicion of a COVID-19 infection
asymptomatic individuals without
is still high. known exposure to COVID-19 who
are undergoing time-sensitive
13. They suggest (conditional
aerosol-generating procedures,
recommendation) RNA testing in
such as a bronchoscopy, when PPE
asymptomatic individuals without
is available.
9. They recommend (conditional known exposure to COVID-19
recommendation) RNA testing in 15. Likewise, they suggest
asymptomatic individuals with no (conditional recommendation) RNA
known contact with COVID-19 who testing in asymptomatic individuals
are being hospitalized in areas with without known exposure to
high prevalence of the disease. They COVID-19 who are undergoing
consider a high prevalence rate to time-sensitive aerosol-generating
be 10% or higher. The IDSA does procedures when PPE is limited
note that if the prevalence rate is and testing is available. For this
between 2% and 9% the decision recommendation, the IDSA gives
to test should be dependent on the greater detail due to restrictions in
availability of testing resources. availability of PPE. They also note
that their recommendation does
10. They suggest (conditional not address the need for repeat
recommendation) performing testing if patients require multiple
only one test in a symptomatic procedures over time.
Besides the 15 recommendations, are sufficient, then testing for the IDSA panel also released their selected asymptomatic individuals algorithm for SARS-CoV-2 Nucleic can be considered. Regardless, the Acid Testing. This algorithm, preferred testing methodology is as seen in Figure 2, separates direct SARS-CoV-2 nucleic acid individuals into symptomatic and amplification testing, such as RT- asymptomatic groups. PCR. The IDSA notes that testing should be prioritized for symptomatic patients first. When resources ISDA ALGORITHM FOR SARS COV-2 NUCLEIC ACID TESTING ***Note: Testing should be prioritized for symptomatic patients first. When resources are adequate, testing for selected asymptomatic individuals should also be considered. Figure 2: IDSA Algorithm for SARS-CoV-2 Nucleic Acid Testing.1 The Infectious Diseases Society of America (IDSA) released their algorithm for nucleic acid testing for COVID-19. According to the IDSA guidelines, testing priority should first be given to symptomatic patients; if resources are available, then testing asymptomatic individuals can be considered. Regardless, patients undergoing time-sensitive immunosuppressive procedures should be tested.4
Making sense of coding possibilities
to track COVID-19 claims for cost
sharing requirements and FWA
In response to COVID-19, many of the changes for their own
organizations began announcing financial gain.8 While the CARES
codes to assist health care systems to Act and related guidance are quiet
properly classify clinical situations on application of FWA, we don’t
of patients and associated services. believe the government intended
The World Health Organization to condone services and payments
(WHO) released emergency ICD10 outside of medical necessity. The
designations, CMS and AMA health plans have an obligation
produced procedure codes for to address FWA and should be
testing, CDC released guidelines prepared to ascertain questionable
for sample collection, WHO claims and systemic abuse and
outlined coding and reporting waste, and standardized coding of
The passing of the FFCRA (March
requirements, and CMS drafted claims is the foundation any post
18th) and CARES Acts7 (March
coding requirements to name a few. process analytical evaluation to
27th) mandated no cost sharing for
detect FWA.
covered members and consequently Additionally, with the legislated
produced an acute need for no cost share requirements, the
identification of services and CS procedure code modifier has
procedures related to diagnosing been resurrected to assist in
COVID 19. The rapid pace of COVID-19 claim identification.
legal changes and uncertainty Plans are racing to ensure proper
associated with coding complicates identification of claims and services
compliance. to remain in compliance and
appropriately apply the cost sharing
Additionally, detection of Fraud,
exemptions without creating overly
Waste and Abuse (FWA) utilizing
broad pathways to reimbursement.
systematic methods would benefit
Inevitably, unscrupulous providers
from standardization of coding in
are attempting to take advantage
claims data sets.Ultimately, the health plans will been exposed to the virus, should
need to establish their own policies Z03.818 – Encounter for use Z11.59 when the test results
specifying appropriate coding observation for suspected are unknown or negative. Once a
methods and the types of services exposure to other biological presumptive positive or definitive
included in “related services” as agents ruled out diagnosis of COVID-19 has been
outlined in the Agency’s FAQ.9 The reached, the diagnosis code U07.1
Z20.828 – Contact with and
following provides an overview should be used.12
(suspected) exposure to other
of the available codes and some
viral communicable diseases PROCEDURE CODES
considerations when building
policies. Z11.59 – Encounter for Briefly, three types of tests can be
screening for other viral performed to ascertain COVID-19
DIAGNOSIS CODES
diseases current or prior infection. PCR
The WHO maintains the ICD10 based testing, which measures
guidelines and published U07.1 – COVID-19, virus the amount of viral RNA, is
recommendations for coding identified definitive for an active, current
and reporting.10 Specifically, infection with great certainty
prior to a definitive diagnosis, and is considered the current
For individuals who may have
the provider should document gold standard. Antibody testing
had exposure to COVID-19 and
signs and symptoms consistent measures the body’s response to
subsequently ruled out, use
with COVID-19 infections and current or prior COVID-19 testing
Z03.818. If the individual had been
if appropriate utilize Z20.828. but is not recommended to be
exposed to the virus (via someone
Standard coding best practices used for determination of an active
who is confirmed or suspected of
utilize the most specific diagnosis infection and does not assess
viral infection) and test results are
codes relevant to the clinical future immunity. Antigen testing
negative or unknown, Z20.828 is
situation. Some signs and assesses the amount of viral surface
the recommended ICD10 code.
symptoms of COVID-19 include, proteins in the patient’s blood
but not limited to, fever, cough, Screening of asymptomatic providing a different method from
shortness of breath, headache, etc.11 individuals who have not knowingly PCR for measuring active disease.
Procedure Code Short description and usage Effective Date
U0001 PCR based testing - utilizing test kits from the CDC to perform the testing 4/1/20
U0002 SPCR based testing – utilizing laboratory developed kits (non-CDC), non-amplified probe 4/1/20
87635 Amplified probe PCR testing 3/13/20
U0003 Amplified probe using high throughput technology 4/14/20
U0004 High throughput technology using any technique 4/14/20
86328 Antibody test - Single step method (e.g. reagent strip) for the detection of COVID-19 4/10/20
86769 Antibody test – Multistep method (e.g. analyzer) for the detection of COVID-19 4/10/20
87299 Infectious agent antigen detection by immunofluorescent technique; not otherwise specified
G2023 Specimen collection from individuals who cannot leave their home 3/1/20
G2024 Specimen collection at a skilled nursing facility or by a lab on behalf of a home health agency 3/1/20As of the publication date, only suitable for antigen testing as the
one antigen testing kit, Quidel methodology for the assay is not
Corporation, was commercially limited to PCR by the CMS code
available13 (FDA EUA issued on May description. However, the closest
8, 2020) and with clinical validity AMA code is 87299 which is a non-
much less than PCR-based testing.14 specific antigen testing code.
However, developments will occur
SAMPLING CODES
in this area and potentially broaden
the capacity and reduce the cost of In addition to testing codes,
testing. CMS released two codes specific
to sample collection: G2023 and
PCR TESTING CODES
G2024. These codes are specific
amplified probe. On April 14, 2020,
In February, CMS announced two for independent laboratories
CMS released to additional codes
codes related to COVID-19 testing, collecting samples from individuals
for high throughput technologies,
U0001 and U0002 with the notice who are home bound (G2023), in a
U0003, amplified probes using
that claims would be accepted with skilled nursing facility (G2024)15 or
high throughput technology, and
these codes on April 1, 2020. U0001 on behalf of a home health agency
U0004, any technique using high
specified tests that were performed (G2024).
throughput technology.
AB TESTING CODES Some commercial plans are
considering these codes to be
On April 10, AMA released two incorporated into the service and
codes, 86328 and 86769, for Ab not separately reimbursable. The
testing specific to COVID-19. The sampling codes are part of an
codes are non-specific to the type interim final rule promulgated by
of antibody detected (i.e. IgG or CMS published on May 8, 2020 in
IgM can be billed with either) and the Federal Register. While they
therefore if two antibodies are are effective, they are subject to a
tested, the code and be billed twice. 60-day comment period.
Single step methods should bill
86328, while multistep methods
using test kits obtained from the
should bill 86769.
CDC. U0002 indicated tests kits
that were developed by a non-CDC ANTIGEN TESTING CODES
laboratory and interestingly, the
analytical requirements were non- Antigen tests will not have been
amplified probe only. received as claims at the time of
this publication, however, two
On March 13, 2020, the American codes are anticipated to be used
Medical Association released 87635 until AMA releases a specific
for PCR based testing using an COVID-19 antigen code. U0002 isBased on this, a single sampler per IDENTIFICATION OF COVID
date of service is sufficient, and CLAIMS
modifier 59’s importance has been
Collectively, claims with COVID-19
reduced. However, during early
related services should be
stages of the outbreak, some claims
identifiable by several methods.
may legitimately represent both
Prior to diagnosis, the WHO18 is
samples and therefore two tests.
recommending coding for signs
Modifier CS represents “cost and symptoms and, as appropriate,
sharing”, and per CMS guidelines17, ICD10 code Z20.828. However,
is a requirement on individual lines the signs and symptoms overlap
of a claim if the service represented with other clinical conditions,
PLA CODES
at the line is to be exempted and therefore alone do not
PLA (Proprietary Laboratory from member responsibility for necessarily ensure the services
Analyses) codes allow for services rendered after March
manufacturers or laboratories to 18, 2020. Further, providers are
more specifically identify their recommended to resubmit prior
tests. As of this publication, one claims with the CS modifier if
laboratory, BioFire, has submitted those services meet the standards
a request for a PLA code to include for exemption from member cost
a bundle COVID-19 and 21 other sharing.
respiratory pathogens.16
While CMS is requiring the use
PROCEDURE CODE of the CS modifier on Medicare
MODIFIERS
claims, several commercial health
Two modifiers are relevant for plans have adopted the same rules
COVID-19 claims. Modifier 59 to make tracking of claims for
indicates additional samples were cost share exemption to be readily rendered leading to a COVID-19
tested on the same date of service identifiable. diagnostic test. To add further
and therefore should both be confusion, claims utilizing Z11.59
billable events. Initially, swabs do not necessarily imply a test was
for both throat and nose were conducted for COVID-19.
collected and processed separately,
Once the member has been
and subsequently, two tests were
diagnosed with COVID-19, claims
performed. CDC changed their
should have the ICD10 code U07.1
recommendation for sample
as the primary diagnosis, unless the
collection to sample the throat only,
member is pregnant, in which case
and if throat and nose are collected,
U07.1 is secondary to the primary
then combine both into a single
diagnosis code of either O98.5 or
sample tube.
O98.51.In both pre-diagnosis and post- samples that should be performed
diagnosis situations, not all per date of service. Inappropriate
services provided on the claim use of the CS modifier for
may be considered related services services unrelated to COVID-19 or
and therefore subject to legislative inappropriate clinical situations
obligations for no cost sharing. (e.g. constipation, allergy status
The CS modifier, which is specific to penicillin, etc.) may indicate
to individual, line level services abusive testing practices.
(as compared to the entire claim),
would appropriately designate Additionally, systematic analytical
services as COVID-19 related analysis of claims data can
rather than non-COVID-19 related rapidly detect patterns of FWA,
acceptable COVID-19 services and such as inappropriate bundling
services. Additionally, as noted,
the expected coding to designate of additional tests or services,
use of CS could better differentiate
the services as COVID-19 related. designating unrelated services
COVID related services from other
The importance of compliance to the cost sharing exemption
unrelated services.
necessitates a concerted, persistent requirements, or tests performed
program for educating ordering without and FDA Emergency Use
providers. Authorization.
OPPORTUNITIES FOR Once identified, the plans standard
IDENTIFICATION OF FRAUD,
protocols for educating providers
WASTE, AND ABUSE
to adjust behavior or further
Despite the flurry of changes and investigative activities up to and
lack of standards for billing, several including involvement of law
options exist for detection of FWA enforcement should be followed.
and can be implemented as either As with any period of uncertainty,
interventional (e.g. claim denials) bad actors will attempt to take
or surveillance and post-payment advantage of the situation.
In summary, the WHO’s codes
analytics.
and instructions regarding coding
and recording COVID-19 cases are Coding specifications or
not aligned with the requirements application of good clinical science
to identify claims and services should be employed. Many of the
leading to and associated with procedure codes should be or are
COVID-19 testing. Therefore, mutually exclusive, and therefore,
the best approach to ensuring simultaneous billing on a claim,
standardized coding of claims, especially routinely by a provider,
proper assignment of cost sharing should raise concern. Definitions
requirements, necessitates that of the codes and agency guidelines19
plans publish a policy outlining also provide limits on the number ofreferences 1. IDSA. IDSA Algorithm for SARS-CoV-2 Nucleic Acid Testing. 2020; https://www.idsociety.org/globalassets/ idsa/practice-guidelines/covid-19/diagnostics/figure-1.png. Accessed 05/13/2020, 2020. 2. CDC, Eckert A, Higgins D. PHIL #23313 Coronavirus. 2020; https://phil.cdc.gov/Details.aspx?pid=23313. Accessed 05/12/2020, 2020. 3. Quidel_Corporation. Sofia 2 SARS Antigen FIA. 2020; https://www.fda.gov/media/137885/download. Ac- cessed 05/12/2020, 2020. 4. IDSA. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19. 2020; https://www. idsociety.org/practice-guideline/covid-19-guideline-diagnostics/. Accessed 05/13/2020, 2020. 5. FDA. Emergency Use Authorization. 2020; https://www.fda.gov/emergency-preparedness-and-response/ mcm-legal-regulatory-and-policy-framework/emergency-use-authorization. Accessed 04/13/2020, 2020. 6. Wulff NH, Tzatzaris M, Young PJ. Monte Carlo simulation of the Spearman-Kaerber TCID50. J Clin Bioin- forma. 2012;2(1):5. 7. For ease of reference, the CARES Act will represent both CARES Act and FFCRA. FAMILIES FIRST CORO- NAVIRUS RESPONSE ACT, Public Law 116–127 (Mar. 18, 2020). CORONAVIRUS AID, RELIEF, AND ECONOM- IC SECURITY ACT, Public Law 116–136 (Mar. 27, 2020). 8. Georgia man arrested for orchestrating scheme to defraud health care benefit programs related to COVID-19 and genetic cancer testing. https://www.fbi.gov/contact-us/field-offices/newark/news/press-releases/geor- gia-man-arrested-for-orchestrating-scheme-to-defraud-health-care-benefit-programs-related-to-covid-19- and-genetic-cancer-testing 9. FAQ on the FFCRA and CARES Act. https://www.cms.gov/files/document/FFCRA-Part-42-FAQs.pdf 10. CDC’s document on the WHO coding and reporting guidelines April 1, 2020 to September 30, 2020. https://www.cdc.gov/nchs/data/icd/COVID-19-guidelines-final.pdf 11. CDC Watch for Symptoms https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html 12. WHO document – Emergency use ICD codes for COVID-19 disease outbreak. https://www.who.int/classifi- cations/icd/covid19/en/ 13. Quidel Press Release. https://ir.quidel.com/news/news-release-details/2020/Quidel-Receives-Emergen- cy-Authorization-for-Rapid-Antigen-COVID-19-Diagnostic-Assay/default.aspx 14. FDA EUA documentation for Quidel’s Sofia2 SARs Antigen FIA. https://www.fda.gov/media/137885/down- load 15. COVID-19 CMS Interim Final Rule, pages 96-98. https://www.cms.gov/files/document/covid-final-ifc.pdf 16. May 2020 PLA public agenda. https://www.ama-assn.org/system/files/2020-04/pla-may-2020-agenda.pdf 17. April 7, 2020 CMS new from Medicare Learning Network – Special Edition. https://www.cms.gov/out- reach-and-educationoutreachffsprovpartprogprovider-partnership-email-archive/2020-04-07-mlnc-se 18. CDC’s document on the WHO coding and reporting guidelines April 1, 2020 to September 30, 2020. https:// www.cdc.gov/nchs/data/icd/COVID-19-guidelines-final.pdf 19. CDC guidelines and sample collection for COVID-19 samples https://www.cdc.gov/coronavirus/2019-ncov/ lab/guidelines-clinical-specimens.html
You can also read
